Newsfeeds - Spark Newswire

2 minute read

Verrica Pharmaceuticals Announces FDA Acceptance Of Filing Of Resubmitted NDA For VP-102 For The Treatment Of Molluscum Contagiosum; Assigns PDUFA goal date of July 23, 2023

Today, 4:08 AM

Assigns PDUFA goal date of July 23, 2023 VP-102 (cantharidin 0.7% Topical Solution) could potentially be the first FDA-approved treatment for molluscum contagiosum, a highly contagious

VRCA

1 minute read

Verrica Reports Pricing Of $32.5M Underwritten Offering Of Common Stock & Pre-Funded Warrants

By Benzinga Newsdesk

Today, 4:08 AM

Verrica announced the pricing of its underwritten offering of 750,000 shares of its common stock and pre-funded warrants to purchase 4,064,814 shares of common stock. The shares of common stock are being sold at a price

VRCA

2 minute read

Earnings

Verrica Pharmaceuticals’s Return On Capital Employed Overview

By Benzinga Insights

Today, 4:08 AM

According to Benzinga Pro, during Q3, Verrica Pharmaceuticals (NASDAQ:VRCA) earned $83 thousand, a 100.82% increase from the preceding…

VRCA

6 minute read

Boeing, PriceSmart And 80 Biggest Movers From Yesterday

By Lisa Levin

Today, 4:08 AM

Gainers Sharps Compliance Corp. (NASDAQ: SMED) shares jumped 196.1% to close at $8.44 on Tuesday after the company it will be acquired by an affiliate of Aurora Capital Partners for $8.75 per share.

AAL

5 minute read

This Low-Float Stock Jumps Around 148%; Here’s 64 Biggest Movers From Yesterday

By Lisa Levin

Today, 4:08 AM

Gainers United Maritime Corporation (NASDAQ: USEA) climbed 147.6% to close at $7.08 on Thursday on heavy momentum following the company's recent listing on the Nasdaq Capital Market.

ABEO

5 minute read

Akerna Shares Dip 53%, Here’s 78 Biggest Movers From Yesterday

By Lisa Levin

Today, 4:08 AM

Gainers Revelation Biosciences, Inc. (NASDAQ: REVB) surged 77.4% to close at $1.11 on Thursday after jumping 27% on Wednesday. Revelation Biosciences recently announced completion of dosing for Phase 1b CLEAR clinical study of REVTx-99b for the treatment of allergic rhinitis.

ADSE

1 minute read

Verrica Announces Proposed Public Offering of Common Stock, Terms Not Disclosed

By Michael Horton

Today, 4:08 AM

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it intends to offer and sell, subject to

VRCA

1 minute read

Analysts Still Believe Verrica’s Ycanth Is Approvable Despite FDA Response Letter

By Vandana Singh

Today, 4:08 AM

Verrica Pharmaceuticals Inc (NASDAQ:VRCA) held a Type A meeting with the FDA regarding the path forward for the resubmission and potential…

VRCA

1 minute read

Verrica Holds Type A Meeting With FDA For Potential Approval Of Skin Infection Candidate

By Ragothaman Srinivasan

Today, 4:08 AM

The U.S. Food and Drug Administration (FDA) convened a Type A meeting with Verrica Pharmaceuticals (NASDAQ: VRCA) regarding the course of action for the clearance of its drug candidate VP-102.

VRCA

1 minute read

Verrica Pharmaceuticals Holds Type A Meeting With FDA For VP-102 For Molluscum Contagiosum

By Bill Haddad

Today, 4:08 AM

Verrica Pharmaceuticals Inc. (Verrica) (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that the Company held a Type A meeting

VRCA